AVTE - Nilai Buku saben Saham Aerovate

Aerovate Therapeutics (AVTE) maintains high margin potential based on its authority in the therapy of severe lung and heart pathologies. The book value per share illustrates the business's fundamental support, where the value 2.58 reflects the metric's balance. Stability is driven by an innovative drug delivery method to the lungs, while management focuses on the final stages of clinical trials for key cardiology programs.

AVTE (Aerovate Therapeutics Inc.) riwayat Nilai Akuntansi Saham saka 04.07.2022 nganti 29.04.2025

Ringkesan rincian data analitis aerovatetx.com (AVTE)

- rega saham lan prakiraan rega para ahli:

Kutipan saham Aerovate|AVTE - Rega prakiraan analis

- statistik kapitalisasi pasar:

Kapitalisasi pasar Aerovate Therapeutics, Inc.|AVTE - Total Nilai Perusahaan

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Aerovate Therapeutics|AVTE - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku aerovatetx.com|AVTE - Aset Perusahaan

- rincian utang lan likuiditas:

Total Utang marang Modal Aerovate Therapeutics|AVTE - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Aerovate Therapeutics, Inc.|AVTE - Kewajiban utang agregat|Utang marang nilai buku Aerovate Therapeutics, Inc.|AVTE - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan Aerovate Therapeutics

Analisis umum perusahaan:Aerovate - AVTE

Produk sing diprodhuksi Aerovate Therapeutics, Inc.

Book value per share reflects the company's net assets minus liabilities, allowing an investor to assess the intrinsic value of the business independently of market fluctuations. When analyzing the book value per share, it should be noted that for Aerovate Therapeutics (AVTE), this metric becomes a critical liquidity indicator amid the cessation of AV-101 development and the potential closure of the company.

Karo sapa Aerovate Therapeutics saingan